&#xa0;
[normal]Written evidence submitted by [bold]ProMetic[bold] [bold]BioSciences[bold] Ltd [bold](BTO0012)[bold]Declaration of interest
[normal]ProMetic
[normal] 
[normal]BioSciences
[normal] Ltd has developed products and technology for the capture of 
[normal]prion
[normal] infectivity from human blood and plasma products and as a consequence has a financial interest in 
[normal]prion
[normal] safety of blood products.
[normal]Executive Summary
[normal]-
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]ProMetic
[normal] Biosciences, in collaboration with the American Red Cross, has developed a technology based upon selective adsorption of 
[normal]prion
[normal] proteins which enables the capture of 
[normal]vCJD
[normal] infectivity from human blood and blood-derived components and products.
[normal]-
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]ProMetic’s
[normal]  technology, commonly referred to as 
[normal]prion
[normal] filtration, has been incorporated into a medical device (P-Capt™) developed in conjunction with and commercialized by 
[normal]Macopharma
[normal] SA which provides increased blood safety by removal of 
[normal]vCJD
[normal] infectivity (if present) from Red Blood Cell Concentrates (RBC). 
[normal]-
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The P-Capt device obtained CE Mark approval in 2006, and since this time has been under evaluation by the UK’s National Blood Service (NHSBT) but never implemented.
[normal]-
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The same technology, in a different format, has been used successfully by Swiss company 
[normal]Octapharma
[normal] AG to provide an increased level of 
[normal]prion
[normal] safety for virally-inactivated (S/D-treated) plasma for transfusion.  
[normal]Octaplas
[normal] LG™ manufactured using 
[normal]ProMetic’s
[normal] 
[normal]prion
[normal] reduction technology has been approved for human administration in several countries including the UK. 
[normal]-
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]In the absence of a commercial blood test with sufficient sensitivity and robustness for use in routine blood donor screening, the adoption of 
[normal]prion
[normal] filtration would provide increased protection against the transmission of 
[normal]vCJD
[normal] via blood and blood-derived products.
[normal]-
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Prion
[normal] reduction technology constitutes a safe and proven approach to improving the safety of blood products independent of the availability of a 
[normal]vCJD
[normal] blood screening test.
[normal]&#xa0;[bold]January 2014
[normal]&#xa0;[bold]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal]&#xa0;
[normal] Reduction of TSE infectivity from human red blood cells using 
[normal]prion
[normal] protein affinity 
[normal]ligands
[normal]. L 
[normal]Gregori
[normal], BC Lambert, PV 
[normal]Gurgel
[normal], L 
[normal]Gheorghiu
[normal], P 
[normal]Edwardson
[normal], JT Lathrop, C 
[normal]MacAuley
[normal], RG 
[normal]Carbonell
[normal], SJ Burton, D Hammond, RG 
[normal]Rohwer
[normal]. Transfusion, 46: 1152-1161, 2006.
[normal] Reduction in infectivity of endogenous transmissible spongiform 
[normal]encephalopaties
[normal] present in blood by adsorption to selective affinity 
[normal]ligands
[normal]. L 
[normal]Gregori
[normal], PV 
[normal]Gurgel
[normal], JT Lathrop, P 
[normal]Edwardson
[normal], BC Lambert, RG 
[normal]Carbonell
[normal], SJ Burton, D Hammond, RG 
[normal]Rohwer
[normal].  Lancet, 368: 2226-2230, 2006.
[normal] 
[normal]Prion
[normal] removal effect of a specific affinity 
[normal]ligand
[normal] introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma 
[normal]OctaplasLG
[normal]. A 
[normal]Neisser-Svae
[normal], A Bailey, L 
[normal]Gregori
[normal], A 
[normal]Heger
[normal], S Jordan, M 
[normal]Behizad
[normal], H 
[normal]Reichl
[normal], J 
[normal]Römisch
[normal], T-E 
[normal]Svae
[normal]. 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal], 97: 226-233, 2009.
[normal] Removal of 
[normal]prion
[normal] infectivity by affinity 
[normal]ligand
[normal] chromatography during 
[normal]OctaplasLG
[normal] manufacturing – results from animal bioassay studies. A 
[normal]Heger
[normal], A Bailey, A 
[normal]Neisser-Svae
[normal], M 
[normal]Ertl
[normal], J 
[normal]Römisch
[normal], T-E 
[normal]Svae
[normal]. 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal], 102: 294-301, 2012.
[normal] Infusion of P-Capt 
[normal]prion
[normal]-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of 
[normal]neoantigen
[normal] formation. JA 
[normal]Cancelas
[normal], N 
[normal]Rugg
[normal], PG Pratt, DN 
[normal]Worsham
[normal], JC 
[normal]Pehta
[normal], K Banks, RD Davenport, WJ Judd. Transfusion, 51: 2228-2236, 2011.
[normal] In vitro assessment of red-cell concentrates in SAG-M filtered through the 
[normal]MacoPharma
[normal] P-CAPT 
[normal]prion
[normal]-reduction filter. CV Murphy, E Eakins, J Fagan, H 
[normal]Croxon
[normal], WG Murphy. Transfusion Medicine, 19: 109-116, 2009.
[normal] Phase I/II safety study of transfusion of 
[normal]prion
[normal]-filtered red cell concentrates in transfusion-dependent patients. MR Cahill, T Murphy, M Kahn, J Fagan, WG Murphy. 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal], 99: 174-176, 2010.
[normal] Characteristics of 
[normal]prion
[normal]-filtered red cells suspended in pathogen-inactivated plasma (MB treated or solvent/detergent treated) for neonatal exchange transfusion. VS 
[normal]Hornsey
[normal], C Casey, K McColl, H Young, O Drummond, L McMillan, A Morrison, CV Prowse. 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal], 101: 28-34, 2011.
[normal] 
[normal]Prion
[normal] reduction of red blood cells: impact on component quality. M Wiltshire, S Thomas, J Scott, V Hicks, M Haines, P Cookson, M Garwood, R Cardigan.  Transfusion, 50: 970-979, 2010.
[normal] 
[normal]https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/212250/SaBTO_10_Dec_2012_final.zip
[normal] Safety of a universal, virus-inactivated and 
[normal]prion
[normal]-depleted pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. P 
[normal]Jilma-Stohlawetz
[normal], FW 
[normal]Kursten
[normal], C 
[normal]Walasek
[normal], M Horvath, G 
[normal]Leitner
[normal], J List, P 
[normal]Quehenberger
[normal], M 
[normal]Schwameis
[normal], J 
[normal]Bartko
[normal], B 
[normal]Jilma
[normal]. Transfusion, 51: 1228-1240, 2011.
[normal] The effect of 
[normal]prion
[normal] reduction in solvent/detergent-treated plasma on haemostatic variables. AS 
[normal]Lawrie
[normal], L Green, MT 
[normal]Canciani
[normal], IJ Mackie, F 
[normal]Peyvandi
[normal], MA Scully, SJ 
[normal]Machin
[normal]. 
[normal]Vox
[normal] 
[normal]Sanguinis
[normal], 99: 232-238, 2010.
[normal]